A Senate panel will look into Mylan's controversial price markups for the Amsterdam-based drugmakers life-saving EpiPen medication, reported NBC News.
The Permanent Subcommittee on Investigations initiated "a preliminary inquiry concerning Mylan Pharmaceuticals' pricing and competition practices with respect to the EpiPen," according to a statement released Wednesday from Sen. Rob Portman (R-Ohio), chairman of the panel, and Sen. Claire McCaskill (D-Mo.).
"Our review of this matter will be robust, thorough and bipartisan," the statement reads. "Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan's sustained price increases."
The inquiry comes two days after New York Attorney General Eric Schneiderman (D) launched an investigation into Mylan over antitrust concerns in the company's contracts with school systems.
More articles on supply chain:
Pediatricians recommend flu vaccination, but not FluMist
Allergan CEO pledges 'social contract' on drug prices
New ad campaign defends drug industry's pricing tactic